A test to predict the spread of clear cell kidney cancer
A PROGNOSTIC ASSAY FOR METASTATIC CLEAR CELL RENAL CELL CARCINOMA
This study is looking to find certain markers in kidney cancer tissues that can help doctors predict which patients might experience faster disease progression, so they can start treatment sooner for those who need it most.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lagrange Scientific, LLC NIH-funded |
| Lab location | 1 site (Pewee Valley, United States) |
| Project ID | NIH-10931950 on NIH RePORTER |
What this research studies
This research aims to develop a prognostic assay that identifies specific biomarkers in clear cell renal cell carcinoma (ccRCC) tissues. By analyzing these biomarkers, the study seeks to predict which patients are at risk of early disease progression to metastasis. This could allow for earlier intervention with systemic therapies, rather than waiting for significant recurrence. The goal is to improve patient outcomes by stratifying those who need aggressive treatment from those who can safely adopt a more conservative management approach.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with clear cell renal cell carcinoma who are at risk of metastasis.
Not a fit: Patients with non-clear cell types of renal carcinoma or those who are not diagnosed with renal cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier and more effective treatment options for patients with aggressive forms of kidney cancer.
How similar studies have performed: Previous research has shown promise in using biomarker panels for cancer prognosis, indicating potential success for this novel approach.
Where this research is happening
Pewee Valley, United States
- Lagrange Scientific, LLC — Pewee Valley, United States (Active)
Researchers
- Principal investigator: Coughlin, Richard Thomas — Lagrange Scientific, LLC
- Study coordinator: Coughlin, Richard Thomas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.